Second only to the fridge handle, the grip of a chef’s knife is likely the most frequently touched surface in your kitchen. Ideally, you want to keep your knives within easy reach. You also want to ...

Ontario has issued $509,100 in penalties against 77 legal representatives and employers for breaking the rules of a program that gives the province the power to pick immigrants who best suit its ...

The VA announced that it has guaranteed its 29 millionth home loan since the program was created in 1944, thanks in part to a 19% increase in VA home loan processing this year compared to the same ...

David Eby's remarks come after similar comments from Conservative Leader Pierre Poilievre, who blamed the program for an employment crisis among young Canadians Author of the article: You can save ...

In a surprise statement, Premier David Eby called for the end of Canada's temporary foreign worker (TFW) program — blaming Ottawa's flawed immigration policies for filling up homeless shelters and ...

Our knowledge of the structure and composition of genomes has progressed in pace with their sequencing. As was expected early on 1, TEs have been found in virtually all eukaryotic species investigated ...

A Co Down councillor is storing Class C drugs in his garage but says they're better locked up there than "flung" across the district. DUP man Alan Lewis says people have been coming to his home ...

OTTAWA—Conservative Leader Pierre Poilievre is calling on Mark Carney’s Liberals to ditch the federal government’s decades-old temporary foreign worker program, taking a harder stance against a ...

Procter & Gamble’s radical strategy of open innovation now produces more than 35% of the company’s innovations and billions of dollars in revenue. by Larry Huston and Nabil Y. Sakkab Procter & Gamble ...

Heteromerge offers a printhead for multimaterial 2PP 3D printing enabling functional additive manufacturing for nano- and micro-scale applications.

The FDA approved imlunestrant for treatment of certain adults with breast cancer who experience disease progression after at least one prior line of endocrine therapy.